Title of SMI goes here



UK standards for microbiology investigations FILLIN "SMI Title front cover" \d "Type SMI Title front cover here <tab+enter>" \o \* MERGEFORMAT National user manual worked example for urine tests -9144001874600AcknowledgmentsUK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website . UK SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see ).The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.For further information please contact us at:Standards UnitNational Infection ServicePublic Health England61 Colindale AvenueLondon NW9 5EQE-mail: standards@.ukWebsite: publication gateway number: 2016401UK Standards for Microbiology Investigations are produced in association with:Logos correct at time of publishing.Contents TOC \o "1-1" \f \t "Heading 2,2,Heading 3,3,*PHE report Heading 1,1,*PHE report heading 2,2,Sub-heading 2x,2,Sub-heading 3x,3,Sub-heading 4,3" Acknowledgments PAGEREF _Toc489877886 \h 2Contents PAGEREF _Toc489877887 \h 3Amendment table PAGEREF _Toc489877888 \h 5UK SMI: scope and purpose PAGEREF _Toc489877889 \h 6User manual template - background PAGEREF _Toc489877890 \h 9Introduction and scope PAGEREF _Toc489877891 \h 10Overview of services offered PAGEREF _Toc489877892 \h 10Locating and contacting the laboratory PAGEREF _Toc489877893 \h 11Consent, collection and transport of specimens PAGEREF _Toc489877894 \h 11Test repertoire PAGEREF _Toc489877895 \h 13Table summary of other laboratory urinary tests PAGEREF _Toc489877896 \h 13Reporting results PAGEREF _Toc489877897 \h 14Interpreting laboratory results PAGEREF _Toc489877898 \h 14Quality assurance and governance PAGEREF _Toc489877899 \h 16References PAGEREF _Toc489877900 \h 18Amendment tableEach UK SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from standards@.uk.New or revised documents should be controlled within the laboratory in accordance with the local quality management system.Amendment number/date-/07.08.17Issue number discarded-Insert issue number1Anticipated next review date*07.08.20Section(s) involvedAmendment*Reviews can be extended up to five years subject to resources available.UK SMI: scope and purposeUsers of UK SMIsPrimarily, UK SMIs are intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK. UK SMIs also provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests. The documents also provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.Background to UK SMIsUK SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages. Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation. Standardisation of the diagnostic process through the application of UK SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.Equal partnership workingUK SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies. The list of participating societies may be found at . Inclusion of a logo in an UK SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing UK SMIs. Nominees of professional societies are members of the Steering Committee and working groups which develop UK SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process. UK SMIs are developed, reviewed and updated through a wide consultation process. Quality assuranceNICE has accredited the process used by the UK SMI working groups to produce UK SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of UK SMIs is certified to ISO 9001:2008. UK SMIs represent a good standard of practice to which all clinical and public health microbiology laboratories in the UK are expected to work. UK SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using UK SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. UK SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. UK SMIs also provide a reference point for method development. The performance of UK SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.Patient and public involvementThe UK SMI working groups are committed to patient and public involvement in the development of UK SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting UK SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access rmation governance and equalityPHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions. The development of UK SMIs is subject to PHE Equality objectives . The UK SMI working groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups. Legal statementWhile every care has been taken in the preparation of UK SMIs, PHE and the partner organisations, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an UK SMI or any information contained therein. If alterations are made by an end user to an UK SMI for local use, it must be made clear where in the document the alterations have been made and by whom such alterations have been made and also acknowledged that PHE and the partner organisations shall bear no liability for such alterations. For the further avoidance of doubt, as UK SMIs have been developed for application within the UK, any application outside the UK shall be at the user’s risk. The evidence base and microbial taxonomy for the UK SMI is as complete as possible at the date of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.UK SMIs are Crown copyright which should be acknowledged where appropriate.Suggested citation for this documentPublic Health England. ( FILLIN "Year of Issue" \d "YYYY <tab+enter>" \o \* MERGEFORMAT 2017). National user manual worked example for urine tests. UK Standards for Microbiology Investigations. U 3 Issue REF NewIssueNumber \* MERGEFORMAT 1. User manual template - backgroundThe user manual template has been developed by a UK SMI joint working group of microbiologists. The document aims to help microbiology service providers produce a comprehensive user manual meeting the current ISO standards. The ISO standards should be used in conjunction with this template ADDIN EN.CITE <EndNote><Cite><Author>Standardization</Author><Year>2012</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5szv5wwrzx020kexw9q5dazepzd5aredspvz" timestamp="1486473840">1</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author>European committee on Standardization,</author></authors></contributors><titles><title>Medical laboratories - Requirements for quality and competence (ISO 15189:2012)</title></titles><pages>1-50</pages><dates><year>2012</year></dates><publisher>British Standards Institution. </publisher><urls></urls><research-notes><style face="bold" font="default" size="100%">A, V</style></research-notes><access-date>10/02/17</access-date></record></Cite></EndNote>1. Duplications within the document are intended to emphasise key points. The document should be considered a template, with suggested headings providing the basis on which individual labs or services can develop their own user manual. The suggested ordering and content of this user manual can be changed but we recommend all suggested content remains included, for example, it may be possible to encompass many elements in a single hyperlinked table of services and tests offered. The microbiology service provider’s user manual is intended as a general resource for practising healthcare professionals.It is recommended that user manuals are made available to general practitioners through their local Clinical Commissioning Group (CCG). Although not intended for public and patient groups, they may find the user manual a useful source of information.The use of plain English is recommended. Introduction and scopeThis guide outlines the process of urinary specimen collection and correct use of the laboratory to obtain results in simple UTI; it does not cover uncommon presentations and pathologies in any detail. It is not a clinical guideline but a short practical guide to the best use of your microbiology laboratory. Women with severe/or ≥ 3 symptoms can be treated empirically without collecting a MSU or dipstick testing.In women with mild/or ≤ 2 symptoms AND Urine not cloudy: 97% negative predictive value (NPV) - do not treat unless there are other risk factors for infection ADDIN EN.CITE <EndNote><Cite><Author>Public Health England</Author><Year>2011</Year><RecNum>4</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="5szv5wwrzx020kexw9q5dazepzd5aredspvz" timestamp="1486729927">4</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author>Public Health England,</author></authors></contributors><titles><title>Urinary tract infections: quick reference guide. Available at - 8</pages><dates><year>2011</year></dates><publisher>PHE</publisher><urls></urls><research-notes><style face="bold" font="default" size="100%">A, V</style></research-notes><access-date>10/02/17</access-date></record></Cite></EndNote>2. Urine is cloudy: use dipstick to guide treatment. Nitrite plus blood or leucocytes has a 92% positive predictive value (PPV); Nitrite, leucocytes, blood all negative has a 76% NPV of UTIConsider a back-up / delayed antibiotic option. Refer to Managing common infections: guidance for primary care.Consider differentials ADDIN EN.CITE <EndNote><Cite><Author>National Institute for Health and Excellence</Author><Year>2015</Year><RecNum>13</RecNum><DisplayText><style face="superscript">3</style></DisplayText><record><rec-number>13</rec-number><foreign-keys><key app="EN" db-id="5szv5wwrzx020kexw9q5dazepzd5aredspvz" timestamp="1490878453">13</key></foreign-keys><ref-type name="Standard">58</ref-type><contributors><authors><author>National Institute for Health and Excellence,</author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Suspected cancer: recognition and referral. Available at </style><style face="underline" font="default" size="100%"> face="normal" font="default" size="100%">.</style></title></titles><pages>1-96</pages><dates><year>2015</year><pub-dates><date>23 June 2015.</date></pub-dates></dates><publisher>National Institute for Health and Excellence,</publisher><isbn>NG12</isbn><urls></urls><research-notes><style face="bold" font="default" size="100%">A, V</style></research-notes><access-date>30/03/2017</access-date></record></Cite></EndNote>3: Infective differentials: sepsis, acute and chronic pyelonephritis, perinephric abscess, cystitis, urethritis, prostatitis, epididymitis, genital infections. Non-infective or pathologies coexisting with UTI: bladder cancer, ovarian cancer and chronic bladder pain syndrome.Blood in urine on dipstick or MSU requires follow up even if thought to be due to UTI to ensure it has cleared. Indications for laboratory urine samples:Indications for pre-treatment urinary laboratory samples are cystitis symptoms in men, pregnant women, children, complex cases for example the immunocompromised. Note: children < 3 months old with suspected UTI should be admitted to hospital. Patients with recurrent UTI or more complex symptoms for example possible pyelonephritis.Routine MSU at ante-natal booking in pregnant women to detect asymptomatic bacteriuria is confirmed by a second MSU and then treated. Follow-up urine samples should be requested after treating asymptomatic bacteriuria in pregnancy to ensure that infection has cleared.MSU should be obtained if there is failure to cure after empirical therapy. Send catheterised samples if there is systemic infection.The guide gives further details of other laboratory tests which are performed on urinary specimens.Overview of services offeredYou should include:detail of basic services (diagnostic testing, clinical advice, infection control, infectious diseases, outbreak management, antibiotic stewardship, etc)listing of specialist areas, for example, regional or national reference facilities and provision of immunoglobulins and vaccines Locating and contacting the laboratoryYou should include:location maps for both outside and inside the hospital (or links to the relevant source)specimen reception opening times and out of hours contact instructionsinstructions on making enquiries for results and requests for additional tests on existing samples availability of clinical advice on ordering of examinations and interpretation of examination resultsdetails of any out-of-hours service or shift system at the laboratory. Outline which services will always be provided and which will only be provided after consultationcontact details for key members of staff including availability times, email addresses of key members of staff, how to obtain results and clinical advice for out of hours service whether the public has access to the laboratory or not and where phlebotomy (and paediatric phlebotomy) services are located clear advice to patients on how to obtain results; explain whether patients should or should not call the laboratory directly for results – indicating consideration of data security and clinical riskConsent, collection and transport of specimensPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYXk8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFyPjxSZWNO

dW0+MTA8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4yLDQt

Nzwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjEwPC9yZWMtbnVtYmVy

Pjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXN6djV3d3J6eDAyMGtleHc5cTVk

YXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0ODY3MzEzMzUiPjEwPC9rZXk+PC9mb3JlaWdu

LWtleXM+PHJlZi10eXBlIG5hbWU9IlJlcG9ydCI+Mjc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+

PGF1dGhvcnM+PGF1dGhvcj5IYXksIEFsYXN0YWlyIEQuLCBCaXJuaWUsSy4sIEJ1c2J5LEouLCBE

ZWxhbmV5LCBCLixEb3duaW5nLCBILiBldCBhbCBvbiBiZWhhbGYgb2YgdGhlIERVVFkgdGVhbSwg

PC9hdXRob3I+PC9hdXRob3JzPjx0ZXJ0aWFyeS1hdXRob3JzPjxhdXRob3I+TmF0aW9uYWwgSW5z

dGl0dXRlIGZvciBIZWFsdGggUmVzZWFyY2guPC9hdXRob3I+PC90ZXJ0aWFyeS1hdXRob3JzPjwv

Y29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlRoZSBEaWFnbm9zaXMgb2YgVXJpbmFyeSBUcmFj

dCBpbmZlY3Rpb24gaW4gWW91bmcgY2hpbGRyZW4gKERVVFkpOiBhIGRpYWdub3N0aWMgcHJvc3Bl

Y3RpdmUgb2JzZXJ2YXRpb25hbCBzdHVkeSB0byBkZXJpdmUgYW5kIHZhbGlkYXRlIGEgY2xpbmlj

YWwgYWxnb3JpdGhtIGZvciB0aGUgZGlhZ25vc2lzIG9mIHVyaW5hcnkgdHJhY3QgaW5mZWN0aW9u

IGluIGNoaWxkcmVuIHByZXNlbnRpbmcgdG8gcHJpbWFyeSBjYXJlIHdpdGggYW4gYWN1dGUgaWxs

bmVzcy48L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SGVhbHRoIFRlY2hub2xvZ3kgQXNzZXNzbWVu

dCAyMDE2PC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHZvbHVtZT4yMDwvdm9sdW1lPjxkYXRl

cz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVseSAyMDE2PC9kYXRlPjwvcHVi

LWRhdGVzPjwvZGF0ZXM+PGFjY2Vzc2lvbi1udW0+MTM2Ni01Mjc4PC9hY2Nlc3Npb24tbnVtPjx1

cmxzPjwvdXJscz48Y3VzdG9tNj41MTwvY3VzdG9tNj48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZh

Y2U9ImJvbGQiIGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPkEsIFY8L3N0eWxlPjwvcmVzZWFy

Y2gtbm90ZXM+PGFjY2Vzcy1kYXRlPjEwLzAyLzE3PC9hY2Nlc3MtZGF0ZT48L3JlY29yZD48L0Np

dGU+PENpdGU+PEF1dGhvcj5OYXRpb25hbCBJbnN0aXR1dGUgZm9yIEhlYWx0aCBhbmQgRXhjZWxs

ZW5jZTwvQXV0aG9yPjxZZWFyPjIwMDc8L1llYXI+PFJlY051bT4yPC9SZWNOdW0+PHJlY29yZD48

cmVjLW51bWJlcj4yPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0iNXN6djV3d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0ODY3

MjkxMDgiPjI8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iUmVwb3J0Ij4yNzwv

cmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5hdGlvbmFsIEluc3RpdHV0

ZSBmb3IgSGVhbHRoIGFuZCBFeGNlbGxlbmNlLDwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1

dG9ycz48dGl0bGVzPjx0aXRsZT5VcmluYXJ5IHRyYWN0IGluZmVjdGlvbiBpbiB1bmRlciAxNnM6

IGRpYWdub3NpcyBhbmQgbWFuYWdlbWVudDwvdGl0bGU+PHRlcnRpYXJ5LXRpdGxlPkNHNTQ8L3Rl

cnRpYXJ5LXRpdGxlPjwvdGl0bGVzPjxwYWdlcz4xIC0gMzY8L3BhZ2VzPjxkYXRlcz48eWVhcj4y

MDA3PC95ZWFyPjwvZGF0ZXM+PHB1Ymxpc2hlcj5OSUNFPC9wdWJsaXNoZXI+PHVybHM+PC91cmxz

PjxyZXNlYXJjaC1ub3Rlcz48c3R5bGUgZmFjZT0iYm9sZCIgZm9udD0iZGVmYXVsdCIgc2l6ZT0i

MTAwJSI+QSwgVjwvc3R5bGU+PC9yZXNlYXJjaC1ub3Rlcz48YWNjZXNzLWRhdGU+MTAvMDIvMTc8

L2FjY2Vzcy1kYXRlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlB1YmxpYyBIZWFsdGgg

RW5nbGFuZDwvQXV0aG9yPjxZZWFyPjIwMTc8L1llYXI+PFJlY051bT4zPC9SZWNOdW0+PHJlY29y

ZD48cmVjLW51bWJlcj4zPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0iNXN6djV3d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0

ODY3Mjk0NjIiPjM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iRWxlY3Ryb25p

YyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlB1

YmxpYyBIZWFsdGggRW5nbGFuZCw8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRp

dGxlcz48dGl0bGU+TWFuYWdlbWVudCBvZiBpbmZlY3Rpb24gZ3VpZGFuY2UgZm9yIHByaW1hcnkg

Y2FyZSBmb3IgY29uc3VsdGF0aW9uIGFuZCBsb2NhbCBhZGFwdGF0aW9uLiBBdmFpbGFibGUgYXQg

aHR0cHM6Ly93d3cuZ292LnVrL2dvdmVybm1lbnQvcHVibGljYXRpb25zL21hbmFnaW5nLWNvbW1v

bi1pbmZlY3Rpb25zLWd1aWRhbmNlLWZvci1wcmltYXJ5LWNhcmUuPC90aXRsZT48L3RpdGxlcz48

cGFnZXM+MSAtIDgyPC9wYWdlcz48ZGF0ZXM+PHllYXI+MjAxNzwveWVhcj48L2RhdGVzPjxwdWJs

aXNoZXI+UEhFPC9wdWJsaXNoZXI+PGFjY2Vzc2lvbi1udW0+MjAxNjA4MTwvYWNjZXNzaW9uLW51

bT48dXJscz48L3VybHM+PHJlc2VhcmNoLW5vdGVzPjxzdHlsZSBmYWNlPSJib2xkIiBmb250PSJk

ZWZhdWx0IiBzaXplPSIxMDAlIj5BLCBWPC9zdHlsZT48L3Jlc2VhcmNoLW5vdGVzPjxhY2Nlc3Mt

ZGF0ZT4xMC8wMi8xNzwvYWNjZXNzLWRhdGU+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+

UHVibGljIEhlYWx0aCBFbmdsYW5kPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVjTnVtPjQ8

L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQ8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48

a2V5IGFwcD0iRU4iIGRiLWlkPSI1c3p2NXd3cnp4MDIwa2V4dzlxNWRhemVwemQ1YXJlZHNwdnoi

IHRpbWVzdGFtcD0iMTQ4NjcyOTkyNyI+NDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBu

YW1lPSJFbGVjdHJvbmljIEFydGljbGUiPjQzPC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRo

b3JzPjxhdXRob3I+UHVibGljIEhlYWx0aCBFbmdsYW5kLDwvYXV0aG9yPjwvYXV0aG9ycz48L2Nv

bnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5VcmluYXJ5IHRyYWN0IGluZmVjdGlvbnM6IHF1aWNr

IHJlZmVyZW5jZSBndWlkZS4gQXZhaWxhYmxlIGF0IGh0dHBzOi8vd3d3Lmdvdi51ay9nb3Zlcm5t

ZW50L3B1YmxpY2F0aW9ucy91cmluYXJ5LXRyYWN0LWluZmVjdGlvbi1kaWFnbm9zaXMuPC90aXRs

ZT48L3RpdGxlcz48cGFnZXM+MSAtIDg8L3BhZ2VzPjxkYXRlcz48eWVhcj4yMDExPC95ZWFyPjwv

ZGF0ZXM+PHB1Ymxpc2hlcj5QSEU8L3B1Ymxpc2hlcj48dXJscz48L3VybHM+PHJlc2VhcmNoLW5v

dGVzPjxzdHlsZSBmYWNlPSJib2xkIiBmb250PSJkZWZhdWx0IiBzaXplPSIxMDAlIj5BLCBWPC9z

dHlsZT48L3Jlc2VhcmNoLW5vdGVzPjxhY2Nlc3MtZGF0ZT4xMC8wMi8xNzwvYWNjZXNzLWRhdGU+

PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+U2NvdHRpc2ggSW50ZXJjb2xsZWdpYXRlIEd1

aWRlbGluZXMgTmV0d29yazwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJlY051bT41PC9SZWNO

dW0+PHJlY29yZD48cmVjLW51bWJlcj41PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBh

cHA9IkVOIiBkYi1pZD0iNXN6djV3d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1l

c3RhbXA9IjE0ODY3MzAyNzMiPjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

RWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48

YXV0aG9yPlNjb3R0aXNoIEludGVyY29sbGVnaWF0ZSBHdWlkZWxpbmVzIE5ldHdvcmssPC9hdXRo

b3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlNJR04gODggLSBNYW5h

Z2VtZW50IG9mIHN1c3BlY3RlZCBiYWN0ZXJpYWwgdXJpbmFyeSB0cmFjdCBpbmZlY3Rpb24gaW4g

YWR1bHRzLiBBdmFpbGFibGUgYXQ6IGh0dHA6Ly93d3cuc2lnbi5hYy51ay9ndWlkZWxpbmVzL2Z1

bGx0ZXh0Lzg4L2luZGV4Lmh0bWwgPC90aXRsZT48dGVydGlhcnktdGl0bGU+U0lHTiA4ODwvdGVy

dGlhcnktdGl0bGU+PC90aXRsZXM+PHBhZ2VzPjEgLSA0NTwvcGFnZXM+PGRhdGVzPjx5ZWFyPjIw

MTI8L3llYXI+PC9kYXRlcz48cHViLWxvY2F0aW9uPkVkaW5idXJnaDwvcHViLWxvY2F0aW9uPjxw

dWJsaXNoZXI+SGVhbHRoIEltcHJvdmVtZW50IFNjb3RsYW5kLjwvcHVibGlzaGVyPjx1cmxzPjwv

dXJscz48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZhY2U9ImJvbGQiIGZvbnQ9ImRlZmF1bHQiIHNp

emU9IjEwMCUiPkEsIFY8L3N0eWxlPjwvcmVzZWFyY2gtbm90ZXM+PGFjY2Vzcy1kYXRlPjEwLzAy

LzE3PC9hY2Nlc3MtZGF0ZT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5IYXk8L0F1dGhvcj48WWVhcj4yMDE2PC9ZZWFyPjxSZWNO

dW0+MTA8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij4yLDQt

Nzwvc3R5bGU+PC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjEwPC9yZWMtbnVtYmVy

Pjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXN6djV3d3J6eDAyMGtleHc5cTVk

YXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0ODY3MzEzMzUiPjEwPC9rZXk+PC9mb3JlaWdu

LWtleXM+PHJlZi10eXBlIG5hbWU9IlJlcG9ydCI+Mjc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+

PGF1dGhvcnM+PGF1dGhvcj5IYXksIEFsYXN0YWlyIEQuLCBCaXJuaWUsSy4sIEJ1c2J5LEouLCBE

ZWxhbmV5LCBCLixEb3duaW5nLCBILiBldCBhbCBvbiBiZWhhbGYgb2YgdGhlIERVVFkgdGVhbSwg

PC9hdXRob3I+PC9hdXRob3JzPjx0ZXJ0aWFyeS1hdXRob3JzPjxhdXRob3I+TmF0aW9uYWwgSW5z

dGl0dXRlIGZvciBIZWFsdGggUmVzZWFyY2guPC9hdXRob3I+PC90ZXJ0aWFyeS1hdXRob3JzPjwv

Y29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlRoZSBEaWFnbm9zaXMgb2YgVXJpbmFyeSBUcmFj

dCBpbmZlY3Rpb24gaW4gWW91bmcgY2hpbGRyZW4gKERVVFkpOiBhIGRpYWdub3N0aWMgcHJvc3Bl

Y3RpdmUgb2JzZXJ2YXRpb25hbCBzdHVkeSB0byBkZXJpdmUgYW5kIHZhbGlkYXRlIGEgY2xpbmlj

YWwgYWxnb3JpdGhtIGZvciB0aGUgZGlhZ25vc2lzIG9mIHVyaW5hcnkgdHJhY3QgaW5mZWN0aW9u

IGluIGNoaWxkcmVuIHByZXNlbnRpbmcgdG8gcHJpbWFyeSBjYXJlIHdpdGggYW4gYWN1dGUgaWxs

bmVzcy48L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SGVhbHRoIFRlY2hub2xvZ3kgQXNzZXNzbWVu

dCAyMDE2PC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHZvbHVtZT4yMDwvdm9sdW1lPjxkYXRl

cz48eWVhcj4yMDE2PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVseSAyMDE2PC9kYXRlPjwvcHVi

LWRhdGVzPjwvZGF0ZXM+PGFjY2Vzc2lvbi1udW0+MTM2Ni01Mjc4PC9hY2Nlc3Npb24tbnVtPjx1

cmxzPjwvdXJscz48Y3VzdG9tNj41MTwvY3VzdG9tNj48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZh

Y2U9ImJvbGQiIGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPkEsIFY8L3N0eWxlPjwvcmVzZWFy

Y2gtbm90ZXM+PGFjY2Vzcy1kYXRlPjEwLzAyLzE3PC9hY2Nlc3MtZGF0ZT48L3JlY29yZD48L0Np

dGU+PENpdGU+PEF1dGhvcj5OYXRpb25hbCBJbnN0aXR1dGUgZm9yIEhlYWx0aCBhbmQgRXhjZWxs

ZW5jZTwvQXV0aG9yPjxZZWFyPjIwMDc8L1llYXI+PFJlY051bT4yPC9SZWNOdW0+PHJlY29yZD48

cmVjLW51bWJlcj4yPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0iNXN6djV3d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0ODY3

MjkxMDgiPjI8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iUmVwb3J0Ij4yNzwv

cmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5hdGlvbmFsIEluc3RpdHV0

ZSBmb3IgSGVhbHRoIGFuZCBFeGNlbGxlbmNlLDwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1

dG9ycz48dGl0bGVzPjx0aXRsZT5VcmluYXJ5IHRyYWN0IGluZmVjdGlvbiBpbiB1bmRlciAxNnM6

IGRpYWdub3NpcyBhbmQgbWFuYWdlbWVudDwvdGl0bGU+PHRlcnRpYXJ5LXRpdGxlPkNHNTQ8L3Rl

cnRpYXJ5LXRpdGxlPjwvdGl0bGVzPjxwYWdlcz4xIC0gMzY8L3BhZ2VzPjxkYXRlcz48eWVhcj4y

MDA3PC95ZWFyPjwvZGF0ZXM+PHB1Ymxpc2hlcj5OSUNFPC9wdWJsaXNoZXI+PHVybHM+PC91cmxz

PjxyZXNlYXJjaC1ub3Rlcz48c3R5bGUgZmFjZT0iYm9sZCIgZm9udD0iZGVmYXVsdCIgc2l6ZT0i

MTAwJSI+QSwgVjwvc3R5bGU+PC9yZXNlYXJjaC1ub3Rlcz48YWNjZXNzLWRhdGU+MTAvMDIvMTc8

L2FjY2Vzcy1kYXRlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlB1YmxpYyBIZWFsdGgg

RW5nbGFuZDwvQXV0aG9yPjxZZWFyPjIwMTc8L1llYXI+PFJlY051bT4zPC9SZWNOdW0+PHJlY29y

ZD48cmVjLW51bWJlcj4zPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0iNXN6djV3d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0

ODY3Mjk0NjIiPjM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iRWxlY3Ryb25p

YyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlB1

YmxpYyBIZWFsdGggRW5nbGFuZCw8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRp

dGxlcz48dGl0bGU+TWFuYWdlbWVudCBvZiBpbmZlY3Rpb24gZ3VpZGFuY2UgZm9yIHByaW1hcnkg

Y2FyZSBmb3IgY29uc3VsdGF0aW9uIGFuZCBsb2NhbCBhZGFwdGF0aW9uLiBBdmFpbGFibGUgYXQg

aHR0cHM6Ly93d3cuZ292LnVrL2dvdmVybm1lbnQvcHVibGljYXRpb25zL21hbmFnaW5nLWNvbW1v

bi1pbmZlY3Rpb25zLWd1aWRhbmNlLWZvci1wcmltYXJ5LWNhcmUuPC90aXRsZT48L3RpdGxlcz48

cGFnZXM+MSAtIDgyPC9wYWdlcz48ZGF0ZXM+PHllYXI+MjAxNzwveWVhcj48L2RhdGVzPjxwdWJs

aXNoZXI+UEhFPC9wdWJsaXNoZXI+PGFjY2Vzc2lvbi1udW0+MjAxNjA4MTwvYWNjZXNzaW9uLW51

bT48dXJscz48L3VybHM+PHJlc2VhcmNoLW5vdGVzPjxzdHlsZSBmYWNlPSJib2xkIiBmb250PSJk

ZWZhdWx0IiBzaXplPSIxMDAlIj5BLCBWPC9zdHlsZT48L3Jlc2VhcmNoLW5vdGVzPjxhY2Nlc3Mt

ZGF0ZT4xMC8wMi8xNzwvYWNjZXNzLWRhdGU+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+

UHVibGljIEhlYWx0aCBFbmdsYW5kPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVjTnVtPjQ8

L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQ8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48

a2V5IGFwcD0iRU4iIGRiLWlkPSI1c3p2NXd3cnp4MDIwa2V4dzlxNWRhemVwemQ1YXJlZHNwdnoi

IHRpbWVzdGFtcD0iMTQ4NjcyOTkyNyI+NDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBu

YW1lPSJFbGVjdHJvbmljIEFydGljbGUiPjQzPC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRo

b3JzPjxhdXRob3I+UHVibGljIEhlYWx0aCBFbmdsYW5kLDwvYXV0aG9yPjwvYXV0aG9ycz48L2Nv

bnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5VcmluYXJ5IHRyYWN0IGluZmVjdGlvbnM6IHF1aWNr

IHJlZmVyZW5jZSBndWlkZS4gQXZhaWxhYmxlIGF0IGh0dHBzOi8vd3d3Lmdvdi51ay9nb3Zlcm5t

ZW50L3B1YmxpY2F0aW9ucy91cmluYXJ5LXRyYWN0LWluZmVjdGlvbi1kaWFnbm9zaXMuPC90aXRs

ZT48L3RpdGxlcz48cGFnZXM+MSAtIDg8L3BhZ2VzPjxkYXRlcz48eWVhcj4yMDExPC95ZWFyPjwv

ZGF0ZXM+PHB1Ymxpc2hlcj5QSEU8L3B1Ymxpc2hlcj48dXJscz48L3VybHM+PHJlc2VhcmNoLW5v

dGVzPjxzdHlsZSBmYWNlPSJib2xkIiBmb250PSJkZWZhdWx0IiBzaXplPSIxMDAlIj5BLCBWPC9z

dHlsZT48L3Jlc2VhcmNoLW5vdGVzPjxhY2Nlc3MtZGF0ZT4xMC8wMi8xNzwvYWNjZXNzLWRhdGU+

PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+U2NvdHRpc2ggSW50ZXJjb2xsZWdpYXRlIEd1

aWRlbGluZXMgTmV0d29yazwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJlY051bT41PC9SZWNO

dW0+PHJlY29yZD48cmVjLW51bWJlcj41PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBh

cHA9IkVOIiBkYi1pZD0iNXN6djV3d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1l

c3RhbXA9IjE0ODY3MzAyNzMiPjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

RWxlY3Ryb25pYyBBcnRpY2xlIj40MzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48

YXV0aG9yPlNjb3R0aXNoIEludGVyY29sbGVnaWF0ZSBHdWlkZWxpbmVzIE5ldHdvcmssPC9hdXRo

b3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlNJR04gODggLSBNYW5h

Z2VtZW50IG9mIHN1c3BlY3RlZCBiYWN0ZXJpYWwgdXJpbmFyeSB0cmFjdCBpbmZlY3Rpb24gaW4g

YWR1bHRzLiBBdmFpbGFibGUgYXQ6IGh0dHA6Ly93d3cuc2lnbi5hYy51ay9ndWlkZWxpbmVzL2Z1

bGx0ZXh0Lzg4L2luZGV4Lmh0bWwgPC90aXRsZT48dGVydGlhcnktdGl0bGU+U0lHTiA4ODwvdGVy

dGlhcnktdGl0bGU+PC90aXRsZXM+PHBhZ2VzPjEgLSA0NTwvcGFnZXM+PGRhdGVzPjx5ZWFyPjIw

MTI8L3llYXI+PC9kYXRlcz48cHViLWxvY2F0aW9uPkVkaW5idXJnaDwvcHViLWxvY2F0aW9uPjxw

dWJsaXNoZXI+SGVhbHRoIEltcHJvdmVtZW50IFNjb3RsYW5kLjwvcHVibGlzaGVyPjx1cmxzPjwv

dXJscz48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZhY2U9ImJvbGQiIGZvbnQ9ImRlZmF1bHQiIHNp

emU9IjEwMCUiPkEsIFY8L3N0eWxlPjwvcmVzZWFyY2gtbm90ZXM+PGFjY2Vzcy1kYXRlPjEwLzAy

LzE3PC9hY2Nlc3MtZGF0ZT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA 2,4-7Urinary Infections – when and how to collect a urinary sampleIn primary care most UTIs occur in women and are limited to the lower urinary tract. link to patient information sheet On the form: include details of relevant clinical information, current, just finished or intended antibiotic therapy in the clinical details space. Urine minimum volume: of 1mL for specimens is required in a plain CE marked leak-proof container for bacterial pathogens. Time to laboratory for plain containers: The specimen should reach the laboratory within 4 hours of collection. Where delays in processing are unavoidable, refrigerate at 4°C (maximum delay 48 hours if refrigerated) or use boric acid containers. Time to laboratory for Boric acid containersPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Qb3J0ZXI8L0F1dGhvcj48WWVhcj4xOTY5PC9ZZWFyPjxS

ZWNOdW0+MTU8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij44

LTEyPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MTU8L3JlYy1udW1i

ZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSI1c3p2NXd3cnp4MDIwa2V4dzlx

NWRhemVwemQ1YXJlZHNwdnoiIHRpbWVzdGFtcD0iMTQ5MzAyNzQ3NiI+MTU8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlBvcnRlciwgSS4gQS48L2F1dGhvcj48YXV0aG9y

PkJyb2RpZSwgSi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0

bGU+Qm9yaWMgYWNpZCBwcmVzZXJ2YXRpb24gb2YgdXJpbmUgc2FtcGxlczwvdGl0bGU+PHNlY29u

ZGFyeS10aXRsZT5CciBNZWQgSjwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkJyIE1lZCBKPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzUz

LTU8L3BhZ2VzPjx2b2x1bWU+Mjwvdm9sdW1lPjxudW1iZXI+NTY1MzwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5CYWN0ZXJpdXJpYS9kaWFnbm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+KkJvcmlj

IEFjaWRzPC9rZXl3b3JkPjxrZXl3b3JkPkNsaW5pY2FsIExhYm9yYXRvcnkgVGVjaG5pcXVlczwv

a2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+S2xlYnNpZWxsYS9pc29s

YXRpb24gJmFtcDsgcHVyaWZpY2F0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPlByb3RldXMvaXNvbGF0

aW9uICZhbXA7IHB1cmlmaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5SZWZyaWdlcmF0aW9uPC9r

ZXl3b3JkPjxrZXl3b3JkPipTcGVjaW1lbiBIYW5kbGluZzwva2V5d29yZD48a2V5d29yZD4qVXJp

bmU8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk2OTwveWVhcj48cHViLWRhdGVz

PjxkYXRlPk1heSAxMDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDctMTQ0NyAo

UHJpbnQpJiN4RDswMDA3LTE0NDcgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjU3Njg0

NjI8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPjxzdHlsZSBmYWNlPSJ1

bmRlcmxpbmUiIGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPmh0dHBzOi8vd3d3Lm5jYmkubmxt

Lm5paC5nb3YvcHVibWVkLzU3Njg0NjI8L3N0eWxlPjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJs

cz48Y3VzdG9tMj5QTUMxOTgzMjcwPC9jdXN0b20yPjxyZXNlYXJjaC1ub3Rlcz48c3R5bGUgZmFj

ZT0iYm9sZCIgZm9udD0iZGVmYXVsdCIgc2l6ZT0iMTAwJSI+QiwgSUk8L3N0eWxlPjwvcmVzZWFy

Y2gtbm90ZXM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+Sm9obnN0b24gSEg8L0F1dGhv

cj48WWVhcj4xOTc4PC9ZZWFyPjxSZWNOdW0+MTk8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXN6djV3

d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0OTMwMjgzNDEiPjE5

PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkJvb2siPjY8L3JlZi10eXBlPjxj

b250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Kb2huc3RvbiBISCwgTW9zcyBNViwgR3V0aHJp

ZSBHQS4sPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlRo

ZSB1c2Ugb2YgYm9yaWMgYWNpZCBmb3IgdGhlIHByZXNlcnZhdGlvbiBvZiBjbGluaWNhbCB1cmlu

ZSBzcGVjaW1lbnMuIEluOiBNZWVycyBQRCwgZWRpdG9yLiBUaGUgYmFjdGVyaW9sb2dpY2FsIGV4

YW1pbmF0aW9uIG9mIHVyaW5lOiBSZXBvcnQgb2YgYSB3b3Jrc2hvcCBvbiBuZWVkcyBhbmQgbWV0

aG9kcy48L3RpdGxlPjwvdGl0bGVzPjxwYWdlcz4yMi0yODwvcGFnZXM+PGRhdGVzPjx5ZWFyPjE5

Nzg8L3llYXI+PC9kYXRlcz48cHViLWxvY2F0aW9uPiBQdWJsaWMgSGVhbHRoIExhYm9yYXRvcnkg

U2VydmljZSBNb25vZ3JhcGggU2VyaWVzIE5vLiAxMCBlZC4gTG9uZG9uOiBITVNPOyA8L3B1Yi1s

b2NhdGlvbj48dXJscz48L3VybHM+PHJlc2VhcmNoLW5vdGVzPjxzdHlsZSBmYWNlPSJib2xkIiBm

b250PSJkZWZhdWx0IiBzaXplPSIxMDAlIj5CLCBJSUk8L3N0eWxlPjwvcmVzZWFyY2gtbm90ZXM+

PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+V2F0c29uPC9BdXRob3I+PFllYXI+MTk3Nzwv

WWVhcj48UmVjTnVtPjE2PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNjwvcmVjLW51bWJl

cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjVzenY1d3dyengwMjBrZXh3OXE1

ZGF6ZXB6ZDVhcmVkc3B2eiIgdGltZXN0YW1wPSIxNDkzMDI3NzQxIj4xNjwva2V5PjwvZm9yZWln

bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29u

dHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+V2F0c29uLCBQLiBHLjwvYXV0aG9yPjxhdXRob3I+

RHVlcmRlbiwgQi4gSS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48

dGl0bGU+TGFib3JhdG9yeSBhc3Nlc3NtZW50IG9mIHBoeXNpY2FsIGFuZCBjaGVtaWNhbCBtZXRo

b2RzIG9mIHByZXNlcnZpbmcgdXJpbmUgc3BlY2ltZW5zPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl

PkogQ2xpbiBQYXRob2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5KIENsaW4gUGF0aG9sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NTMy

LTY8L3BhZ2VzPjx2b2x1bWU+MzA8L3ZvbHVtZT48bnVtYmVyPjY8L251bWJlcj48a2V5d29yZHM+

PGtleXdvcmQ+QmFjdGVyaWEvZHJ1ZyBlZmZlY3RzL2lzb2xhdGlvbiAmYW1wOyBwdXJpZmljYXRp

b248L2tleXdvcmQ+PGtleXdvcmQ+Qm9yaWMgQWNpZHMvcGhhcm1hY29sb2d5PC9rZXl3b3JkPjxr

ZXl3b3JkPkVzY2hlcmljaGlhIGNvbGkvZHJ1ZyBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPkh1

bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPlBvdmlkb25lL3Bo

YXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD4qUHJlc2VydmF0aW9uLCBCaW9sb2dpY2FsPC9r

ZXl3b3JkPjxrZXl3b3JkPlJlZnJpZ2VyYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+U29kaXVtIENo

bG9yaWRlL3BoYXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD4qVXJpbmUvbWljcm9iaW9sb2d5

PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjE5Nzc8L3llYXI+PHB1Yi1kYXRlcz48

ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDIxLTk3NDYgKFByaW50

KSYjeEQ7MDAyMS05NzQ2IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4zMjY4MTc8L2Fj

Y2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPjxzdHlsZSBmYWNlPSJ1bmRlcmxp

bmUiIGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzMyNjgxNzwvc3R5bGU+PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0

b20yPlBNQzQ3NjQ2MzwvY3VzdG9tMj48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZhY2U9ImJvbGQi

IGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPkIsIElJPC9zdHlsZT48L3Jlc2VhcmNoLW5vdGVz

PjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPk5pY2thbmRlcjwvQXV0aG9yPjxZZWFyPjE5

ODI8L1llYXI+PFJlY051bT4xODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MTg8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSI1c3p2NXd3cnp4MDIwa2V4

dzlxNWRhemVwemQ1YXJlZHNwdnoiIHRpbWVzdGFtcD0iMTQ5MzAyODExOSI+MTg8L2tleT48L2Zv

cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+

PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5pY2thbmRlciwgSy4gSy48L2F1dGhvcj48

YXV0aG9yPlNoYW5ob2x0emVyLCBDLiBKLjwvYXV0aG9yPjxhdXRob3I+UGV0ZXJzb24sIEwuIFIu

PC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlVyaW5lIGN1

bHR1cmUgdHJhbnNwb3J0IHR1YmVzOiBlZmZlY3Qgb2Ygc2FtcGxlIHZvbHVtZSBvbiBiYWN0ZXJp

YWwgdG94aWNpdHkgb2YgdGhlIHByZXNlcnZhdGl2ZTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5K

IENsaW4gTWljcm9iaW9sPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1

bGwtdGl0bGU+SiBDbGluIE1pY3JvYmlvbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2Vz

PjU5My01PC9wYWdlcz48dm9sdW1lPjE1PC92b2x1bWU+PG51bWJlcj40PC9udW1iZXI+PGtleXdv

cmRzPjxrZXl3b3JkPkJhY3RlcmlhLypncm93dGggJmFtcDsgZGV2ZWxvcG1lbnQ8L2tleXdvcmQ+

PGtleXdvcmQ+Qm9yaWMgQWNpZHMvKnBoYXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD5Fc2No

ZXJpY2hpYSBjb2xpL2dyb3d0aCAmYW1wOyBkZXZlbG9wbWVudDwva2V5d29yZD48a2V5d29yZD5G

b3JtYXRlcy9waGFybWFjb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+R2x5Y2Vyb2wvcGhhcm1hY29s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPktsZWJzaWVsbGEgcG5ldW1vbmlhZS9ncm93dGggJmFtcDsg

ZGV2ZWxvcG1lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+U3BlY2ltZW4gSGFuZGxpbmcvKmluc3RydW1l

bnRhdGlvbjwva2V5d29yZD48a2V5d29yZD5TdGFwaHlsb2NvY2N1cy9ncm93dGggJmFtcDsgZGV2

ZWxvcG1lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+VXJpbmUvKm1pY3JvYmlvbG9neTwva2V5d29yZD48

L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTgyPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+QXByPC9k

YXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDA5NS0xMTM3IChQcmludCkmI3hEOzAwOTUt

MTEzNyAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+NzA0MDQ1OTwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+PHN0eWxlIGZhY2U9InVuZGVybGluZSIgZm9udD0i

ZGVmYXVsdCIgc2l6ZT0iMTAwJSI+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQv

NzA0MDQ1OTwvc3R5bGU+PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzI3

MjE1MDwvY3VzdG9tMj48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZhY2U9ImJvbGQiIGZvbnQ9ImRl

ZmF1bHQiIHNpemU9IjEwMCUiPkIsIElJPC9zdHlsZT48L3Jlc2VhcmNoLW5vdGVzPjwvcmVjb3Jk

PjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPk1lZXJzPC9BdXRob3I+PFllYXI+MTk5MDwvWWVhcj48UmVj

TnVtPjE3PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNzwvcmVjLW51bWJlcj48Zm9yZWln

bi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjVzenY1d3dyengwMjBrZXh3OXE1ZGF6ZXB6ZDVh

cmVkc3B2eiIgdGltZXN0YW1wPSIxNDkzMDI4MDUzIj4xNzwva2V5PjwvZm9yZWlnbi1rZXlzPjxy

ZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3Jz

PjxhdXRob3JzPjxhdXRob3I+TWVlcnMsIFAuIEQuPC9hdXRob3I+PGF1dGhvcj5DaG93LCBDLiBL

LjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1l

bnQgb2YgTWljcm9iaW9sb2d5LCBOYXRpb25hbCBVbml2ZXJzaXR5IG9mIFNpbmdhcG9yZS48L2F1

dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5CYWN0ZXJpb3N0YXRpYyBhbmQgYmFjdGVyaWNpZGFs

IGFjdGlvbnMgb2YgYm9yaWMgYWNpZCBhZ2FpbnN0IGJhY3RlcmlhIGFuZCBmdW5naSBjb21tb25s

eSBmb3VuZCBpbiB1cmluZTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5KIENsaW4gUGF0aG9sPC9z

ZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBDbGluIFBh

dGhvbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjQ4NC03PC9wYWdlcz48dm9sdW1l

PjQzPC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFjaW5ldG9i

YWN0ZXIvZHJ1ZyBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPkJhY3RlcmlhLypkcnVnIGVmZmVj

dHM8L2tleXdvcmQ+PGtleXdvcmQ+Qm9yaWMgQWNpZHMvKnBoYXJtYWNvbG9neTwva2V5d29yZD48

a2V5d29yZD5DYW5kaWRhIGFsYmljYW5zLypkcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+

Q29sb255IENvdW50LCBNaWNyb2JpYWw8L2tleXdvcmQ+PGtleXdvcmQ+RG9zZS1SZXNwb25zZSBS

ZWxhdGlvbnNoaXAsIERydWc8L2tleXdvcmQ+PGtleXdvcmQ+RW50ZXJvYmFjdGVyaWFjZWFlL2Ry

dWcgZWZmZWN0czwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJl

c2VydmF0aW9uLCBCaW9sb2dpY2FsPC9rZXl3b3JkPjxrZXl3b3JkPlBzZXVkb21vbmFzIGFlcnVn

aW5vc2EvZHJ1ZyBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPlN0YXBoeWxvY29jY3VzL2RydWcg

ZWZmZWN0czwva2V5d29yZD48a2V5d29yZD5TdHJlcHRvY29jY3VzL2RydWcgZWZmZWN0czwva2V5

d29yZD48a2V5d29yZD5VcmluZS8qbWljcm9iaW9sb2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRh

dGVzPjx5ZWFyPjE5OTA8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0

ZXM+PC9kYXRlcz48aXNibj4wMDIxLTk3NDYgKFByaW50KSYjeEQ7MDAyMS05NzQ2IChMaW5raW5n

KTwvaXNibj48YWNjZXNzaW9uLW51bT4yMTE2NDUzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxh

dGVkLXVybHM+PHVybD48c3R5bGUgZmFjZT0idW5kZXJsaW5lIiBmb250PSJkZWZhdWx0IiBzaXpl

PSIxMDAlIj5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMTE2NDUzPC9zdHls

ZT48L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNTAyNTAyPC9jdXN0b20y

PjxyZXNlYXJjaC1ub3Rlcz48c3R5bGUgZmFjZT0iYm9sZCIgZm9udD0iZGVmYXVsdCIgc2l6ZT0i

MTAwJSI+QiwgSUk8L3N0eWxlPjwvcmVzZWFyY2gtbm90ZXM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Qb3J0ZXI8L0F1dGhvcj48WWVhcj4xOTY5PC9ZZWFyPjxS

ZWNOdW0+MTU8L1JlY051bT48RGlzcGxheVRleHQ+PHN0eWxlIGZhY2U9InN1cGVyc2NyaXB0Ij44

LTEyPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MTU8L3JlYy1udW1i

ZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSI1c3p2NXd3cnp4MDIwa2V4dzlx

NWRhemVwemQ1YXJlZHNwdnoiIHRpbWVzdGFtcD0iMTQ5MzAyNzQ3NiI+MTU8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlBvcnRlciwgSS4gQS48L2F1dGhvcj48YXV0aG9y

PkJyb2RpZSwgSi48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0

bGU+Qm9yaWMgYWNpZCBwcmVzZXJ2YXRpb24gb2YgdXJpbmUgc2FtcGxlczwvdGl0bGU+PHNlY29u

ZGFyeS10aXRsZT5CciBNZWQgSjwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkJyIE1lZCBKPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MzUz

LTU8L3BhZ2VzPjx2b2x1bWU+Mjwvdm9sdW1lPjxudW1iZXI+NTY1MzwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5CYWN0ZXJpdXJpYS9kaWFnbm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+KkJvcmlj

IEFjaWRzPC9rZXl3b3JkPjxrZXl3b3JkPkNsaW5pY2FsIExhYm9yYXRvcnkgVGVjaG5pcXVlczwv

a2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+S2xlYnNpZWxsYS9pc29s

YXRpb24gJmFtcDsgcHVyaWZpY2F0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPlByb3RldXMvaXNvbGF0

aW9uICZhbXA7IHB1cmlmaWNhdGlvbjwva2V5d29yZD48a2V5d29yZD5SZWZyaWdlcmF0aW9uPC9r

ZXl3b3JkPjxrZXl3b3JkPipTcGVjaW1lbiBIYW5kbGluZzwva2V5d29yZD48a2V5d29yZD4qVXJp

bmU8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk2OTwveWVhcj48cHViLWRhdGVz

PjxkYXRlPk1heSAxMDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDctMTQ0NyAo

UHJpbnQpJiN4RDswMDA3LTE0NDcgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjU3Njg0

NjI8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPjxzdHlsZSBmYWNlPSJ1

bmRlcmxpbmUiIGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPmh0dHBzOi8vd3d3Lm5jYmkubmxt

Lm5paC5nb3YvcHVibWVkLzU3Njg0NjI8L3N0eWxlPjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJs

cz48Y3VzdG9tMj5QTUMxOTgzMjcwPC9jdXN0b20yPjxyZXNlYXJjaC1ub3Rlcz48c3R5bGUgZmFj

ZT0iYm9sZCIgZm9udD0iZGVmYXVsdCIgc2l6ZT0iMTAwJSI+QiwgSUk8L3N0eWxlPjwvcmVzZWFy

Y2gtbm90ZXM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+Sm9obnN0b24gSEg8L0F1dGhv

cj48WWVhcj4xOTc4PC9ZZWFyPjxSZWNOdW0+MTk8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iNXN6djV3

d3J6eDAyMGtleHc5cTVkYXplcHpkNWFyZWRzcHZ6IiB0aW1lc3RhbXA9IjE0OTMwMjgzNDEiPjE5

PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkJvb2siPjY8L3JlZi10eXBlPjxj

b250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Kb2huc3RvbiBISCwgTW9zcyBNViwgR3V0aHJp

ZSBHQS4sPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlRo

ZSB1c2Ugb2YgYm9yaWMgYWNpZCBmb3IgdGhlIHByZXNlcnZhdGlvbiBvZiBjbGluaWNhbCB1cmlu

ZSBzcGVjaW1lbnMuIEluOiBNZWVycyBQRCwgZWRpdG9yLiBUaGUgYmFjdGVyaW9sb2dpY2FsIGV4

YW1pbmF0aW9uIG9mIHVyaW5lOiBSZXBvcnQgb2YgYSB3b3Jrc2hvcCBvbiBuZWVkcyBhbmQgbWV0

aG9kcy48L3RpdGxlPjwvdGl0bGVzPjxwYWdlcz4yMi0yODwvcGFnZXM+PGRhdGVzPjx5ZWFyPjE5

Nzg8L3llYXI+PC9kYXRlcz48cHViLWxvY2F0aW9uPiBQdWJsaWMgSGVhbHRoIExhYm9yYXRvcnkg

U2VydmljZSBNb25vZ3JhcGggU2VyaWVzIE5vLiAxMCBlZC4gTG9uZG9uOiBITVNPOyA8L3B1Yi1s

b2NhdGlvbj48dXJscz48L3VybHM+PHJlc2VhcmNoLW5vdGVzPjxzdHlsZSBmYWNlPSJib2xkIiBm

b250PSJkZWZhdWx0IiBzaXplPSIxMDAlIj5CLCBJSUk8L3N0eWxlPjwvcmVzZWFyY2gtbm90ZXM+

PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+V2F0c29uPC9BdXRob3I+PFllYXI+MTk3Nzwv

WWVhcj48UmVjTnVtPjE2PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNjwvcmVjLW51bWJl

cj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjVzenY1d3dyengwMjBrZXh3OXE1

ZGF6ZXB6ZDVhcmVkc3B2eiIgdGltZXN0YW1wPSIxNDkzMDI3NzQxIj4xNjwva2V5PjwvZm9yZWln

bi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29u

dHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+V2F0c29uLCBQLiBHLjwvYXV0aG9yPjxhdXRob3I+

RHVlcmRlbiwgQi4gSS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48

dGl0bGU+TGFib3JhdG9yeSBhc3Nlc3NtZW50IG9mIHBoeXNpY2FsIGFuZCBjaGVtaWNhbCBtZXRo

b2RzIG9mIHByZXNlcnZpbmcgdXJpbmUgc3BlY2ltZW5zPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl

PkogQ2xpbiBQYXRob2w8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5KIENsaW4gUGF0aG9sPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+NTMy

LTY8L3BhZ2VzPjx2b2x1bWU+MzA8L3ZvbHVtZT48bnVtYmVyPjY8L251bWJlcj48a2V5d29yZHM+

PGtleXdvcmQ+QmFjdGVyaWEvZHJ1ZyBlZmZlY3RzL2lzb2xhdGlvbiAmYW1wOyBwdXJpZmljYXRp

b248L2tleXdvcmQ+PGtleXdvcmQ+Qm9yaWMgQWNpZHMvcGhhcm1hY29sb2d5PC9rZXl3b3JkPjxr

ZXl3b3JkPkVzY2hlcmljaGlhIGNvbGkvZHJ1ZyBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPkh1

bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPlBvdmlkb25lL3Bo

YXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD4qUHJlc2VydmF0aW9uLCBCaW9sb2dpY2FsPC9r

ZXl3b3JkPjxrZXl3b3JkPlJlZnJpZ2VyYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+U29kaXVtIENo

bG9yaWRlL3BoYXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD4qVXJpbmUvbWljcm9iaW9sb2d5

PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjE5Nzc8L3llYXI+PHB1Yi1kYXRlcz48

ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDIxLTk3NDYgKFByaW50

KSYjeEQ7MDAyMS05NzQ2IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4zMjY4MTc8L2Fj

Y2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPjxzdHlsZSBmYWNlPSJ1bmRlcmxp

bmUiIGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzMyNjgxNzwvc3R5bGU+PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0

b20yPlBNQzQ3NjQ2MzwvY3VzdG9tMj48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZhY2U9ImJvbGQi

IGZvbnQ9ImRlZmF1bHQiIHNpemU9IjEwMCUiPkIsIElJPC9zdHlsZT48L3Jlc2VhcmNoLW5vdGVz

PjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPk5pY2thbmRlcjwvQXV0aG9yPjxZZWFyPjE5

ODI8L1llYXI+PFJlY051bT4xODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MTg8L3JlYy1u

dW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSI1c3p2NXd3cnp4MDIwa2V4

dzlxNWRhemVwemQ1YXJlZHNwdnoiIHRpbWVzdGFtcD0iMTQ5MzAyODExOSI+MTg8L2tleT48L2Zv

cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+

PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5pY2thbmRlciwgSy4gSy48L2F1dGhvcj48

YXV0aG9yPlNoYW5ob2x0emVyLCBDLiBKLjwvYXV0aG9yPjxhdXRob3I+UGV0ZXJzb24sIEwuIFIu

PC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPlVyaW5lIGN1

bHR1cmUgdHJhbnNwb3J0IHR1YmVzOiBlZmZlY3Qgb2Ygc2FtcGxlIHZvbHVtZSBvbiBiYWN0ZXJp

YWwgdG94aWNpdHkgb2YgdGhlIHByZXNlcnZhdGl2ZTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5K

IENsaW4gTWljcm9iaW9sPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1

bGwtdGl0bGU+SiBDbGluIE1pY3JvYmlvbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2Vz

PjU5My01PC9wYWdlcz48dm9sdW1lPjE1PC92b2x1bWU+PG51bWJlcj40PC9udW1iZXI+PGtleXdv

cmRzPjxrZXl3b3JkPkJhY3RlcmlhLypncm93dGggJmFtcDsgZGV2ZWxvcG1lbnQ8L2tleXdvcmQ+

PGtleXdvcmQ+Qm9yaWMgQWNpZHMvKnBoYXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD5Fc2No

ZXJpY2hpYSBjb2xpL2dyb3d0aCAmYW1wOyBkZXZlbG9wbWVudDwva2V5d29yZD48a2V5d29yZD5G

b3JtYXRlcy9waGFybWFjb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+R2x5Y2Vyb2wvcGhhcm1hY29s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPktsZWJzaWVsbGEgcG5ldW1vbmlhZS9ncm93dGggJmFtcDsg

ZGV2ZWxvcG1lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+U3BlY2ltZW4gSGFuZGxpbmcvKmluc3RydW1l

bnRhdGlvbjwva2V5d29yZD48a2V5d29yZD5TdGFwaHlsb2NvY2N1cy9ncm93dGggJmFtcDsgZGV2

ZWxvcG1lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+VXJpbmUvKm1pY3JvYmlvbG9neTwva2V5d29yZD48

L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTgyPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+QXByPC9k

YXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDA5NS0xMTM3IChQcmludCkmI3hEOzAwOTUt

MTEzNyAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+NzA0MDQ1OTwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+PHN0eWxlIGZhY2U9InVuZGVybGluZSIgZm9udD0i

ZGVmYXVsdCIgc2l6ZT0iMTAwJSI+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQv

NzA0MDQ1OTwvc3R5bGU+PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPlBNQzI3

MjE1MDwvY3VzdG9tMj48cmVzZWFyY2gtbm90ZXM+PHN0eWxlIGZhY2U9ImJvbGQiIGZvbnQ9ImRl

ZmF1bHQiIHNpemU9IjEwMCUiPkIsIElJPC9zdHlsZT48L3Jlc2VhcmNoLW5vdGVzPjwvcmVjb3Jk

PjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPk1lZXJzPC9BdXRob3I+PFllYXI+MTk5MDwvWWVhcj48UmVj

TnVtPjE3PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNzwvcmVjLW51bWJlcj48Zm9yZWln

bi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjVzenY1d3dyengwMjBrZXh3OXE1ZGF6ZXB6ZDVh

cmVkc3B2eiIgdGltZXN0YW1wPSIxNDkzMDI4MDUzIj4xNzwva2V5PjwvZm9yZWlnbi1rZXlzPjxy

ZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3Jz

PjxhdXRob3JzPjxhdXRob3I+TWVlcnMsIFAuIEQuPC9hdXRob3I+PGF1dGhvcj5DaG93LCBDLiBL

LjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1l

bnQgb2YgTWljcm9iaW9sb2d5LCBOYXRpb25hbCBVbml2ZXJzaXR5IG9mIFNpbmdhcG9yZS48L2F1

dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5CYWN0ZXJpb3N0YXRpYyBhbmQgYmFjdGVyaWNpZGFs

IGFjdGlvbnMgb2YgYm9yaWMgYWNpZCBhZ2FpbnN0IGJhY3RlcmlhIGFuZCBmdW5naSBjb21tb25s

eSBmb3VuZCBpbiB1cmluZTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5KIENsaW4gUGF0aG9sPC9z

ZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBDbGluIFBh

dGhvbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjQ4NC03PC9wYWdlcz48dm9sdW1l

PjQzPC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFjaW5ldG9i

YWN0ZXIvZHJ1ZyBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPkJhY3RlcmlhLypkcnVnIGVmZmVj

dHM8L2tleXdvcmQ+PGtleXdvcmQ+Qm9yaWMgQWNpZHMvKnBoYXJtYWNvbG9neTwva2V5d29yZD48

a2V5d29yZD5DYW5kaWRhIGFsYmljYW5zLypkcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+

Q29sb255IENvdW50LCBNaWNyb2JpYWw8L2tleXdvcmQ+PGtleXdvcmQ+RG9zZS1SZXNwb25zZSBS

ZWxhdGlvbnNoaXAsIERydWc8L2tleXdvcmQ+PGtleXdvcmQ+RW50ZXJvYmFjdGVyaWFjZWFlL2Ry

dWcgZWZmZWN0czwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJl

c2VydmF0aW9uLCBCaW9sb2dpY2FsPC9rZXl3b3JkPjxrZXl3b3JkPlBzZXVkb21vbmFzIGFlcnVn

aW5vc2EvZHJ1ZyBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPlN0YXBoeWxvY29jY3VzL2RydWcg

ZWZmZWN0czwva2V5d29yZD48a2V5d29yZD5TdHJlcHRvY29jY3VzL2RydWcgZWZmZWN0czwva2V5

d29yZD48a2V5d29yZD5VcmluZS8qbWljcm9iaW9sb2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRh

dGVzPjx5ZWFyPjE5OTA8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KdW48L2RhdGU+PC9wdWItZGF0

ZXM+PC9kYXRlcz48aXNibj4wMDIxLTk3NDYgKFByaW50KSYjeEQ7MDAyMS05NzQ2IChMaW5raW5n

KTwvaXNibj48YWNjZXNzaW9uLW51bT4yMTE2NDUzPC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxh

dGVkLXVybHM+PHVybD48c3R5bGUgZmFjZT0idW5kZXJsaW5lIiBmb250PSJkZWZhdWx0IiBzaXpl

PSIxMDAlIj5odHRwczovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMTE2NDUzPC9zdHls

ZT48L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNTAyNTAyPC9jdXN0b20y

PjxyZXNlYXJjaC1ub3Rlcz48c3R5bGUgZmFjZT0iYm9sZCIgZm9udD0iZGVmYXVsdCIgc2l6ZT0i

MTAwJSI+QiwgSUk8L3N0eWxlPjwvcmVzZWFyY2gtbm90ZXM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT5=

ADDIN EN.CITE.DATA 8-12: Boric acid 1–2% holds the bacterial population steady for 48–96 hours, and other cellular components remain intact. Boric acid may be inhibitory to some organisms and may inhibit dipstick tests for leucocyte esterase. If boric acid preservative is used, ensure that the container is filled up to the line and the contents mixed well.picture of collection container(s)MSU (midstream specimen of urine) collectionThe first part of voided urine is discarded and, without interrupting the flow, approximately 10mL is collected into a CE marked leak proof container (plain or boric acid). Clean catch urine collectionPeriurethral cleaning is recommended. The whole specimen is collected and then an aliquot sent for examination in a CE marked leak proof container (plain or boric acid).CSU (catheter sample of urine) collectionThe sample may be obtained either from a transient (‘in and out’) catheterisation or from an indwelling catheter. In the latter case, the specimen is obtained aseptically from a sample port in the catheter tubing or by aseptic aspiration of the tubing. The specimen should not be obtained from the collection bag. Approximately 10mL is collected into a CE marked leak proof container (plain or boric acid).Please ensure that any urine samples obtained from ‘in and out’ catheterisation are notified clearly as this may affect how the sample is processed and reported in the laboratory. Ileal conduit or urostomy specimen collectionUse a plain CE marked leak-proof container. Urine is obtained via a catheter passed aseptically into the stomal opening after removal of the external appliance. Results from this type of specimen may be difficult to interpret. Pad collection After washing the nappy area thoroughly, a pad is placed inside the nappy. As soon as the pad is wet with urine (but no faecal soiling), push the tip of a syringe into the pad and draw urine into the syringe. Transfer specimen to a CE marked leak-proof container. If difficulty is experienced in withdrawing urine, the wet fibres may be inserted into the syringe barrel and the urine squeezed directly into the container with the syringe plunger. In young children, diagnostic accuracy has been shown to be greater for clean-catch than nappy pad samples: primary care clinicians should prioritise the use of clean-catch sampling wherever possible.SPA (suprapubic aspirate), cystoscopic, nephrostomy, expressed prostatic secretions or ureteric collection Use a plain CE marked leak-proof container. Note: Urine catheters, bag urines, catheter tips and ureteric stents are not acceptable sample types. Meares and Stamey localisation culture method for diagnosis of prostatitis The following specimens are collected in a plain CE marked leak-proof container:the initial 5–8mL voided urine (urethral urine)MSU (bladder urine)expressed prostatic secretions following prostatic massagethe first 2–3mL voided urine following prostatic massageTest repertoireYou should include the following:examinations offered by the laboratory. Include logical listings or tables of tests and turnaround times), primary sample volumes, specific specimen containers, special precautions, and procedures for medico-legal samples details of relevant clinical algorithms, with links to local or national policies lists of referred tests, including the names, addresses and accreditation status of laboratories to which work is routinely referreda table to state the duration of storage for samples that may need re-testing, with information on disease incubation periods, testing interval and time limits for requesting additional tests You may also wish to include information on the costs of tests.Investigation Container (sample volume) Laboratory Turnaround time Time limit for requesting additional investigations Cost of test Further info Urine culture ? MSU ? Clean catch ? CSU Plain universal container (1-10 mL) OR Primary urine tubes (often used for automated systems) OR Boric acid container (fill to line)16-72 hours 24 hours See notes above Urine culture ? Cystoscopic ? SPA ? Ureteric ? Ileal conduit ? Urostomy ? Pad Expressed prostatic secretionsPlain universal container (1-10 mL) 16-72 hours 24 hours See notes above Table summary of other laboratory urinary tests Investigation Container (sample volume) Laboratory Turnaround time Time limit for requesting additional investigations Cost of test Further info Urine TB culture Refer to UK SMI B 40: Investigation of specimens for Mycobacterium species.Plain container 250 or 500mL N/A Early morning urine x3. Label as ‘high risk Urine chlamydia and gonorrhoea detection screeningScreening sexually active under 25s annually or change of sexual partner. Note: vaginal sample is preferred in womenFirst 20mL catch into container with fluidUrine sample obtained after not having passed urine for one hoursee genital infectionsUrine chlamydia and gonorrhoea not screeningNote: vaginal sample is preferred in womenFirst 20mL catch into container with fluidUrine sample obtained after not having passed urine for one hoursee genital infectionsUrine for Schistosoma haemotobium (Bilharzia) microscopy Refer to UK SMI B 31: Investigation of specimens other than blood for parasitesPlain container 250 or 500mLCollect all urine between 10am and 2pm Alternatively, 24hr collection of terminal urine samples are occasionally taken which may be helpfulParasitic cause of haematuria: eggs detected in urineUrine bacterial antigen detection (Legionella & Streptococcus pneumoniae) Plain universal container (1-10 mL) The test for legionella antigen only detects L. pneumophila serogroup 1 For further information on urine testing, refer to UK Standards for Microbiology Investigations, UK SMI B 41 - Investigation of urine.Reporting resultsYou should include the following: provide instructions for making result enquiriesadvice to review electronic reporting systems before phoning for resultsexplanation of different report status categories (interim, final, amended)Interpreting laboratory results Adverse factors affecting the interpretation of urine culture results: contamination of the sample at the point of collection delay >4 hours in arrival at laboratoryexcessive temperatureincorrect sample type (for example bag urine)incorrect sample volume (if boric acid containers are used)incomplete clinical details on request form Note: rapid transport to the laboratory is the best way to minimise uncertainty of results. Significant pyuria: The occurrence of ≥107 WBC/L is significant, although higher numbers of WBC (white blood cells) may be found in healthy, asymptomatic women. A level of >108 WBC/L may be more appropriate in discriminating infection. Where a significant growth is present, absence of pyuria in adult patients makes a diagnosis of UTI less likely, but does not exclude it. For interpretation of microscopy (and culture) results, appropriate guidance should be followed.Diagnosis of prostatitis may be achieved by comparing the levels of pyuria in sequential specimens taken in association with prostatic massage. If the level of pyuria after prostatic massage is 10 times that of the initial urine, then bacterial prostatitis is likely. More than 15 WBCs per high power field in expressed prostatic secretions is considered abnormal, even if the WBCs in the urethral and bladder urine are within the normal range.Sterile pyuria (with no growth on routine culture media and persistent presence of WBCs in urine). Consider:prior treatment with antimicrobial agentscatheterisation nephritis calculi (stones) bladder neoplasmssexually transmitted diseases or other infection with a difficult to grow organismrenal tuberculosis Bacterial growths:Bacterial growths of ≥108 colony forming units (cfu)/L (105 cfu/mL) are consistent with infection and counts below this usually indicate contamination. A pure growth (single organism) with counts between 107 and 108 cfu/L should be evaluated based on clinical information or confirmed by repeat culture. The probability of UTI is increased by the isolation of the same organism from two specimens. However, in some patient groups counts ≥105 cfu/L may be significant. Interpretation of culture results must be made with care and take into account adverse factors in specimen collection and mon causes are: E. coli and Proteus species, then Klebsiella species and Enterobacter species. (Note: Urease-producing organisms such as Proteus mirabilis may be associated with renal stone formation).In pregnancy, organisms are as above plus Staphylococcus saprophyticus.In CSU, organisms are as above plus Pseudomonas species, Enterococcus species, S. aureus and Candida species.S. aureus is unusual except in CSU or perineum contamination in women. In men a secondary source is likely.Children MSUs and bacterial growths:A pure growth of between 107-108 cfu/L (104-105 cfu/mL) is consistent with UTI in a carefully taken specimen from a child but it can be difficult to get clean samples.CSU and bacterial growths:May not accurately reflect the true bladder pathogen and often contains several bacterial species. Urine cultures may not reflect bladder bacteriuria because sampled organisms may have arisen from biofilms on the inner surface of the catheter. Quality of specimen collection and clinical circumstances in the individual patient are critical in the interpretation of bacterial counts. In specimens from long term-catheterised patients, interpretation of significance on the basis of bacterial counts alone may be impossible. Catheterisation is occasionally used to collect a contamination free sample (‘in and out’) when any bacterial growth is significant: these results should be interpreted in the same way as MSUs. Other lab reported findings:Note: It should be noted that the other laboratory reported findings below should be adopted locally as not all laboratories report these now. Squamous epithelial cells – may be due to skin contamination of sampleRed blood cells – requires follow up to exclude serious pathologyHyaline casts - Large numbers of hyaline casts are associated with renal disease, but may also be found in patients with fever or following strenuous exerciseGranular and cellular casts - indicate pyelonephritis or glomerulonephritisRBC casts - RBC casts usually indicate glomerular bleeding and are excreted in large numbers in the acute phase of glomerulonephritis Quality assurance and governanceYou should include details of:the quality assurance and governance structure for the laboratorythe complaints procedurethe laboratory’s policy on protection of personal information; and the fax and email policyensure that the manual is consistent with ISO15189 guidance (reference the ISO guidance in this section) ADDIN EN.CITE <EndNote><Cite><Author>Standardization</Author><Year>2012</Year><RecNum>1</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="5szv5wwrzx020kexw9q5dazepzd5aredspvz" timestamp="1486473840">1</key></foreign-keys><ref-type name="Electronic Article">43</ref-type><contributors><authors><author>European committee on Standardization,</author></authors></contributors><titles><title>Medical laboratories - Requirements for quality and competence (ISO 15189:2012)</title></titles><pages>1-50</pages><dates><year>2012</year></dates><publisher>British Standards Institution. </publisher><urls></urls><research-notes><style face="bold" font="default" size="100%">A, V</style></research-notes><access-date>10/02/17</access-date></record></Cite></EndNote>1a statement on the accreditation status, link to the accreditation body, and list of which (if any) tests are excluded from the accredited scope of practice (accreditation status of test repertoire)how to obtain validation/verification datacompliance with Human Tissue ActReferencesModified GRADE table used by UK SMIs when assessing referencesGrading of Recommendations, Assessment, Development, and Evaluation (GRADE) is a systematic approach to assessing references. A modified GRADE method is used in UK SMIs for appraising references for inclusion. Each reference is assessed and allocated a grade for strength of recommendation (A-D) and quality of the underlying evidence (I-VI). A summary table which defines the grade is listed below and should be used in conjunction with the reference list.Strength of recommendationQuality of evidenceA Strongly recommendedI Evidence from randomised controlled trials, meta-analysis and systematic reviewsB Recommended but other alternatives may be acceptableII Evidence from non-randomised studiesC Weakly recommended: seek alternativesIII Non-analytical studies, for example, case reports, reviews, case seriesD Never recommendedIV Expert opinion and wide acceptance as good practice but with no study evidence V Required by legislation, code of practice or national standard VI Letter or other ADDIN EN.REFLIST 1.European committee on Standardization. Medical laboratories - Requirements for quality and competence (ISO 15189:2012). British Standards Institution. . 1-50. 2012. A, V2.Public Health England. Urinary tract infections: quick reference guide. Available at . PHE. 1 - 8. 2011. A, V3. Suspected cancer: recognition and referral. Available at .: National Institute for Health and Excellence,; 2015. p. 1-96. A, V4.Hay AD, Birnie,K., Busby,J., Delaney, B.,Downing, H. et al on behalf of the DUTY team, . The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. Research. NIfH 2016. A, V5.National Institute for Health and Excellence. Urinary tract infection in under 16s: diagnosis and management 2007. 1 - 36. A, V6.Public Health England. Management of infection guidance for primary care for consultation and local adaptation. Available at . PHE. 1 - 82. 2017. A, V7.Scottish Intercollegiate Guidelines Network. SIGN 88 - Management of suspected bacterial urinary tract infection in adults. Available at: Health Improvement Scotland. 1 - 45. 2012. A, V8.Porter IA, Brodie J. Boric acid preservation of urine samples. Br Med J 1969;2:353-5. B, II9.Johnston HH MM, Guthrie GA., The use of boric acid for the preservation of clinical urine specimens. In: Meers PD, editor. The bacteriological examination of urine: Report of a workshop on needs and methods. Public Health Laboratory Service Monograph Series No. 10 ed. London: HMSO; ; 1978. B, III10.Watson PG, Duerden BI. Laboratory assessment of physical and chemical methods of preserving urine specimens. J Clin Pathol 1977;30:532-6. B, II11.Nickander KK, Shanholtzer CJ, Peterson LR. Urine culture transport tubes: effect of sample volume on bacterial toxicity of the preservative. J Clin Microbiol 1982;15:593-5. B, II12.Meers PD, Chow CK. Bacteriostatic and bactericidal actions of boric acid against bacteria and fungi commonly found in urine. J Clin Pathol 1990;43:484-7. B, II ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download